Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Feucht

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Biorxiv : the Preprint Server for Biology|March 11, 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Research Square|October 16, 2023
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunctionCorina Amor, Inés Fernández-Maestre, Saria Chowdhury, et al.
Nature Aging|January 24, 2024
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunctionCorina Amor, Inés Fernández-Maestre, Saria Chowdhury, et al.
Science (New York, N.Y.)|December 22, 2018
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combinationMarcus Ruscetti, Josef Leibold, Matthew J Bott, et al.
Nature Cancer|July 22, 2025
CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Cancer Discovery|May 8, 2020
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer MetastasisJosef Leibold, Marcus Ruscetti, Zhen Cao, et al.
Nature Medicine|January 14, 2022
HLA-independent T cell receptors for targeting tumors with low antigen densityJorge Mansilla-Soto, Justin Eyquem, Sascha Haubner, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Cancer|January 6, 2026
CAR-adapted PIK3CD base editing enhances T cell anti-tumor potencyPhilip Bucher, Nadine Brückner, Jule Kortendieck, et al.
Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Biorxiv : the Preprint Server for Biology|March 11, 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Research Square|October 16, 2023
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunctionCorina Amor, Inés Fernández-Maestre, Saria Chowdhury, et al.
Nature Aging|January 24, 2024
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunctionCorina Amor, Inés Fernández-Maestre, Saria Chowdhury, et al.
Science (New York, N.Y.)|December 22, 2018
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combinationMarcus Ruscetti, Josef Leibold, Matthew J Bott, et al.
Nature Cancer|July 22, 2025
CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Cancer Discovery|May 8, 2020
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer MetastasisJosef Leibold, Marcus Ruscetti, Zhen Cao, et al.
Nature Medicine|January 14, 2022
HLA-independent T cell receptors for targeting tumors with low antigen densityJorge Mansilla-Soto, Justin Eyquem, Sascha Haubner, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Cancer|January 6, 2026
CAR-adapted PIK3CD base editing enhances T cell anti-tumor potencyPhilip Bucher, Nadine Brückner, Jule Kortendieck, et al.
Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.
Pageof 4